Philips (PHG) Q1 2026 earnings review
Order Growth Returns; Margin Expansion Sustained in Q1
Philips delivered a solid start to 2026 with 4% comparable sales growth and a 40 bps expansion in Adjusted EBITA margin to 9.0%. While sales grew across all segments, momentum was led by Personal Health (+9%). Order intake returned to growth at 6%, signaling a healthy pipeline. Management reiterated its 2026 outlook, citing confidence in productivity gains and innovation, despite ongoing tariff and inflation headwinds.
🐂 Bull Case
A 6% increase in comparable order intake and a 4% YoY rise in the order book provide clear revenue visibility, with order book accounting for ~40% of revenue.
The company achieved EUR 126 million in savings this quarter and remains firmly on track to hit its EUR 1.5 billion 2026-2028 target, helping to offset external inflationary pressures.
🐻 Bear Case
Tariffs and cost inflation remain significant headwinds. Connected Care margins were particularly impacted this quarter, contracting 60 bps YoY.
While overall growth was positive, Connected Care’s EBITA margin remains the lowest in the group at 2.9%, with ongoing pressure from cost absorption issues.
⚖️ Verdict: 🟢
Bullish. Philips is executing well on its operational restructuring and innovation pipeline. The return to consistent sales growth and the ability to expand margins despite significant external tariff costs suggest the turnaround strategy is maturing.
Key Themes
Personal Health Outperformance
Personal Health is the clear growth leader with 9% comparable sales growth and a robust 15.8% Adjusted EBITA margin. Double-digit growth in emerging markets and strength in mature geographies demonstrate the power of the core grooming and oral care portfolio.
Connected Care Margin Pressure
Connected Care Adjusted EBITA margin fell to 2.9% (vs 3.5% in Q1 2025). Despite 3% sales growth, higher tariffs and cost inflation, combined with lower cost absorption, continue to compress profitability in this division.
Accelerating AI Portfolio
Philips is successfully pivoting to an AI-first model. Recent launches like SmartHeart (automated MR imaging) and DeviceGuide (real-time cardiac guidance) are driving demand and differentiating the portfolio in a competitive MedTech landscape.
Other KPIs
Expansion of 40 bps. Margin improvement was driven by operational productivity and favorable mix, showing resilience against a -3.2% combined headwind from inflation and tariffs.
Improved from negative territory (EUR -1.09B in Q1 2025), largely due to the absence of the large Respironics recall-related settlement payments that hit the prior year.
Guidance
Management reiterated the outlook. Performance is stable, with all quarters expected to fall within this range. Diagnosis & Treatment is expected at the lower end, while Connected Care and Personal Health trend to the upper end.
Stable outlook maintained. The company relies on sustained productivity initiatives to offset lingering inflationary pressures throughout the year.
Key Questions
Connected Care Recovery
Given the persistent margin pressure in Connected Care, what specific milestones should investors look for regarding a recovery to historical margin levels?
Tariff Mitigation
With tariff impacts still a net negative, is there any visibility on when these supply chain 'regionalization' efforts will provide a net positive contribution to margins?
China Market Dynamics
Greater China remains 'cautious' according to the presentation. Are there signs of a worsening competitive environment or is the weakness strictly macro-related?